All In Biotech

Drug Trial Radar · NCT07223697

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

An Extension Study To Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Atopic Dermatitis Who Participated in Previous Afimkibart Clinical Trials

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jan 8, 2026

Primary completion

Mar 1, 2033

Study completion Mar 1, 2033

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Nov 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.

Conditions

  • Atopic Dermatitis

Interventions

  • AfimkibartDrug

    Afimkibart SC injection will be administered as per the schedule defined in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants with Adverse EventsTime frame: From Baseline up to 6 years

Locations

31 sites in 7 countries. Site status is shown where the registry gives one.

  • UCLA Division of Dermatology

    Los Angeles, California

  • Dermatology Research Associate

    Los Angeles, California

  • Olympian Clinical Research

    Tampa, Florida

  • Hamilton Research, LLC

    Alpharetta, Georgia

  • Revival Research Institute, LLC

    Troy, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Best Skin Research LLC

    Camp Hill, Pennsylvania

  • Instituto Brasil de Pesquisa Clínica-IBPCLIN S/A

    Rio de Janeiro, Brazil

  • Centro de Estudos em Terapias Inovadoras ? CETI

    Curitiba, Paraná, Brazil

  • Irmandade Da Santa Casa de Misericordia de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital de Clnicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil

  • UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu

    Botucatu, São Paulo, Brazil

  • Centro de Pesquisa São Lucas

    Campinas, São Paulo, Brazil

  • HMCG - Hospital e Maternidade Dr. Christovo da Gama

    Santo Andr, São Paulo, Brazil

  • Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto Hospital de Base - PPDS

    Sao Jose Rio Preto, São Paulo, Brazil

  • DermEffects

    London, Ontario, Canada

  • Lynderm Research Inc

    Markham, Ontario, Canada

  • DermEdge Research

    Mississauga, Ontario, Canada

  • Ryan Clinical Research Inc

    Newmarket, Ontario, Canada

  • Dermatologikum Hamburg Gemeinschaftspraxis GbR

    Hamburg, Germany

  • Fachklinik Bad Bentheim

    Bad Bentheim, Lower Saxony, Germany

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    Rome, Lazio, Italy

  • Azienda Ospedaliero Universitaria delle Marche

    Ancona, The Marches, Italy

  • Centrum Medyczne Pratia Gdynia

    Gdynia, Poland

  • Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy Marek Brzewski, Pawel Brzewski s.c.

    Krakow, Poland

  • Centrum Nowoczesnych Terapii "Dobry Lekarz"

    Krakow, Poland

  • Uniwersytecki Szpital Kliniczny im.Fryderyka Chopina w Rzeszowie

    Rzeszów, Poland

  • Klinika Ambroziak Dermatologia

    Warsaw, Poland

  • Centrum Medyczne Pratia Katowice I

    Katowice, Silesian Voivodeship, Poland

  • Hospital Universitario Reina Sofia

    Córdoba, Spain

  • Clinica Universidad de Navarra

    Pamplona, Navarre, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.